Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Chemokine receptor CXCR3B is implicated in cancer inhibition and angiogenesis.
• Hepatocellular carcinoma (HCC) is a significant global health concern.
• The specific role of CXCR3B in HCC progression requires further elucidation.

Purpose of the Study:

• To investigate the function of CXCR3B in a hepatocellular carcinoma cell model (SK-Hep1).
• To determine the impact of CXCR3B blockade on cancer cell behavior and immune cell interactions.

Main Methods:

• CXCR3B expression was blocked in SK-Hep1 cells.
• Cell viability, cell cycle, and apoptosis were assessed using MTT and flow cytometry.
• Cell migration, invasion, and NK-92 cell cytotoxicity were evaluated using various assays.
• Expression of NK cell activating receptors was measured via flow cytometry.

Main Results:

• CXCR3B blockade did not affect SK-Hep1 cell viability, cell cycle, or apoptosis.
• Blocking CXCR3B significantly increased SK-Hep1 cell migration, invasion, and expression of slug, vimentin, and N-cadherin.
• CXCR3B blockade reduced NK-92 cell cytotoxicity against SK-Hep1 and inhibited NK cell activating receptors (NKp30+, NKG2D+, NKG2C+).

Conclusions:

• CXCR3B appears to play a suppressive role in hepatocellular carcinoma.
• CXCR3B may exert its tumor-suppressive function by enhancing natural killer cell cytotoxicity against HCC cells.